Shares of Zynex (NASDAQ:ZYXI) increased 2.65% in after-market trading after the company reported Q2 results.
Earnings per share were up 50.00% year over year to $0.09, which were in line with the estimate of $0.09.
Revenue of $19,263,000 up by 87.07% year over year, which beat the estimate of $19,120,000.
Zynex hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Jul 28, 2020
Time: 04:15 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1487/36138
Recent Stock Performance
Company's 52-week high was at $29.73
Company's 52-week low was at $7.51
Price action over last quarter: Up 15.12%
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.
See more from Benzinga
- Earnings Scheduled For July 28, 2020
- Benzinga's Top Upgrades, Downgrades For July 20, 2020
- 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.